Sirion Therapeutics (drug rights) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Sirion Therapeutics (drug rights) General Information

Description

United States rights for DUREZOL and emulsion and global rights for ZYCLORIN. DUREZOL emulsion is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. ZYCLORIN is a topical ophthalmic immunomodulator and immunosuppressive agent.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Primary Office
  • 3110 Cherry Palm Drive
  • Suite 340
  • Tampa, FL 33619
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sirion Therapeutics (drug rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.

Request a free trial

Sirion Therapeutics (drug rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sirion Therapeutics (drug rights)‘s full profile, request access.

Request a free trial